
    
      This is an open-label extension study to evaluate the safety and efficacy of Canagliflozin
      (TA-7284) in combination with insulin in Japanese patients with Type 2 diabetes mellitus, who
      are not optimally controlled on diet and exercise. The patients will enroll from the
      double-blind study of 16 weeks and receive TA-7284 100mg orally for 36 weeks.
    
  